Rather than bolting ML onto the existing drug discovery process, Isomorphic Labs is reimagining everything from first principles with an AI-first approach, leveraging machine learning to build predictive and generative models of biological phenomena to understand how novel drugs could perform. The company differentiates itself from other AI-driven drug discovery startups by being a direct subsidiary of Alphabet, with access to resources, computing power, and partnerships with teams within DeepMind.

AI-driven drug discovery itself may not be novel, but the approach the company is taking, as well as its direct links with Alphabet, Google, and DeepMind present great potential for the company to disrupt the market with the best talent and technology.